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Summary
Background.— Percutaneous transcatheter closure of patent foramen ovale has been proposed
to prevent recurrent strokes in young adults. Contrast transcranial Doppler ultrasonography
provides a functional, semiquantitative evaluation of right-to-left cardiac shunt.Patent foramen
ovale;
Aims.— To evaluate the efﬁcacy of percutaneous closure of patent foramen ovale in suppressing
right-to-left shunt (assessed using transcranial Doppler) and in preventing secondary stroke.
Abbreviations: ASA, Atrial septum aneurysm; ASD, Atrial septal defect; CT, Computed tomography; ECG, Electrocardiogram; IVC,
Inferior vena cava; MES, Microembolic signals; MRI, Magnetic resonance imaging; PFO, Patent foramen ovale; R/L, Right-to-left; TCD,
Transcranial Doppler; TEE, Transesophageal echocardiography; TIA, Transient ischaemic attack; TTE, Transthoracic echocardiography.
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conﬁguration du foramen ovale. Des études complémentaires sont nécessaires pour conﬁrmer
cette hypothèse.
© 2008 Elsevier Masson SAS. All rights reserved.
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ecent studies have shown that patent foramen ovale (PFO)
s associated signiﬁcantly with cryptogenic stroke in the
oung patient [1]. A wide opening of the PFO [2] and its
ssociation with atrial septal aneurysm (ASA) [3] have
een identiﬁed as indicators of a particularly high stroke
isk. Transesophageal echocardiography (TEE) with contrast
njection is considered to be the investigation of choice for
etecting right-to-left (R/L) shunt associated with PFO, and
or excluding other cardioembolic causes of stroke. How-
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tver, estimation of the PFO size by TEE remains difﬁcult [4].
ontrast transcranial Doppler (TCD) ultrasonography is an
lternative method for detecting R/L shunts [5,6] and pro-
ides a semiquantitative evaluation of the R/L shunt in the
rain [7]. Percutaneous PFO closure has been proposed as
n alternative strategy to surgery or long-term anticoagula-F. van de Wyngaert et al.
Methods.— Sixty-six patients less than 55 years of age were selected from 81 consecutive
patients evaluated for percutaneous closure of patent foramen ovale after one or more crypto-
genic stroke. All patients presented with a right-to-left cardiac shunt and passage of more than
50 microbubbles or curtain pattern on transcranial Doppler. Follow-up tests included cardiac
and neurological clinical evaluation, contrast transcranial Doppler, and echocardiography.
Results.— Percutaneous closure was successful in all patients, without major persistent side-
effects. Before closure, the rate of recurrent stroke events was 16.57 per 100 patient-years;
after closure, no recurrent stroke events (including transient ischaemic attacks) occurred during
a mean follow-up period of 3.73 years (p = 0.0001). Contrast transcranial Doppler detected
residual right-to-left cardiac shunt in 25/60 (41.7%) patients evaluated after 12 months; 20.0%
of these patients had passage of more than 50 microbubbles on transcranial Doppler.
Conclusion.— Contrast transcranial Doppler is a useful tool in the selection of patients for
percutaneous closure of patent foramen ovale. The absence of recurrent stroke events after
transcatheter closure suggests that this procedure may prevent stroke by changing the foramen
ovale conﬁguration, even in cases of persisting shunt. Larger studies are needed to conﬁrm
these data.
© 2008 Elsevier Masson SAS. All rights reserved.
Résumé
Historique.— La fermeture percutanée du foramen ovale perméable est proposée pour prévenir
la récidive d’accident vasculaire cérébral chez le jeune adulte. Le doppler transcrânien réa-
lisé avec injection de contraste permet une évaluation semi-quantitative du shunt cardiaque
droit—gauche.
Objectif.— Le but de l’étude est d’évaluer l’efﬁcacité de la fermeture percutanée du foramen
ovale perméable dans la prévention secondaire de l’accident vasculaire cérébral et dans la
disparition de shunt droit—gauche mis en évidence par doppler transcrânien.
Méthodologie.— Soixante-six patients âgés de moins de 55 ans et ayant présenté au moins un
accident vasculaire cérébral cryptogénique ont été retenus parmi 81 patients adressés consécu-
tivement pour fermeture percutanée d’un foramen ovale perméable. Tous présentaient un
shunt cardiaque droit—gauche avec passage de contraste au doppler transcrânien de plus de 50
microbulles ou un signe du « rideau ». Le suivi clinique cardiologique et neurologique fut associé
à un suivi par doppler transcrânien et par échocardiographie.
Résultats.— Avant fermeture, le taux de récidive d’accident vasculaire cérébral était de 16,57
par 100 années-patients. La fermeture fut réalisée avec succès chez tous sans effets secondaires
majeurs persistants. Aucune récidive d’accident ischémique transitoire, ni d’accident vascu-
laire cérébral ne survint pendant un suivi moyen de 3,73 ans (p = 0,0001). Les contrôles par
doppler transcrânien ont détecté une incidence de 41,7 % de shunts cardiaques droit—gauche
résiduels après une année parmi lesquels 20 % avec passage de plus de 50 microbulles.
Conclusions.— Le doppler transcrânien réalisé avec injection de contraste est utile pour sélec-
tionner les patients avant fermeture percutanée d’un foramen ovale perméable. L’absence de
récidive d’accident vasculaire cérébral malgré la persistance d’un shunt résiduel suggère que
la fermeture percutanée pourrait prévenir les récidives d’accident vasculaire en modiﬁant laion in the prevention of recurrent stroke [8]. We conducted
prospective study of the percutaneous closure of PFO in
atients whose shunt was discovered after one or more
ryptogenic stroke. The purpose of the study was to assess
he efﬁcacy of percutaneous PFO closure in preventing sec-
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TAbsence of recurrent stroke after percutaneous closure of P
ondary stroke events (including transient ischaemic attack
[TIA]) by the correction of signiﬁcant R/L shunting.
Patients and methods
Patients
Eligible patients had experienced one or more crypto-
genic stroke. Diagnosis of cryptogenic stroke was based
on unequivocal acute focal neurological deﬁcit due to
a cerebral ischaemic lesion, demonstrated by computed
tomography (CT) scan and/or cerebral magnetic resonance
imaging (MRI), with the exclusion of all possible causes other
than a PFO.
Normal results were required for the following examina-
tions:
• cerebral MRI, except for the ischaemic lesions;
• angio-MRI of the circle of Willis, and— in selected doubtful
cases— cerebral angiography;
• continuous wave Doppler and color duplex echography of
extracranial cervical arteries;
• 12-lead electrocardiogram (ECG);
• 24 h electrocardiographic Holter monitoring;
• TEE, except for the presence of PFO with or without ASA;
• standard TCD ultrasonography.
Routine blood tests and an extensive work-up were car-
ried out to exclude hypercoagulable status (i.e. antithrom-
bin deﬁciency, protein C or S deﬁciency, antiphospholipid
antibody syndrome, hyperhomocysteinaemia, activated pro-
tein C resistance, factor V Leiden mutation, prothrombin
G20210A gene mutation).
Echocardiography
PFO was demonstrated by transthoracic echocardiography
(TTE) and/or TEE with R/L interatrial shunting of contrast at
rest and/or during a Valsalva manoeuvre. Contrast medium
consisted of 1mL air mixed with 9mL saline solution, and
was injected rapidly into an antecubital vein via a 20 gauge
catheter. Passage of a signiﬁcant number of microbubbles
on TEE during three cardiac cycles [9] was required if a
patient was to be considered for PFO closure. ASA was
deﬁned as abnormally redundant interatrial septum with
an excursion greater than or equal to 10mm [4] into the
right atrium or the left atrium, and was noted but not
required.
Transcranial Doppler microembolic signal
detection
TCD ultrasonography detection of microembolic signals
(MES) was performed using a Multidop X-4 TCD 8 (DWL®)
monitoring device. The middle cerebral arteries were mon-
itored simultaneously through the temporal window using
multigate 2MHz probes. TCD probes were ﬁtted to a light
metal frame, which was ﬁxed ﬁrmly to the head by two
earpieces and an adjustable nose saddle (manufactured by
DWL). A scale between −50 and +150 cm/s with an 8mm
axial length of the sample volume, a 128-point fast Fourier
transform resolution, and detection thresholds of 9 dB above
r
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he Doppler background were used to identify MES and
temporal delay between the different samples on each
robe. Data from both channels were recorded onto a hard
isk. All patients had appropriate echo windows with ade-
uate echo signals.
The contrast medium used was the same as that used for
EE, consisting of agitated saline. During the test, with the
atient lying comfortably in the supine position, 10mL of
ontrast medium were injected into a large antecubital vein
ia a 20 gauge catheter (twice at rest, three times with a Val-
alva manoeuvre for 5—10 s starting 5 s after the start of the
njection, and once while coughing). The following deﬁnition
f MES was used: typical, visible and audible, short-duration,
igh-intensity signal within the Doppler ﬂow spectrum, with
time delay in the two channels within each side [10]. Two
xperienced observers counted the separate MES on the two
ides during ofﬂine analysis. An uncountable signal pattern
aused by a high number of MES during a very short period
as called a curtain pattern, as described previously [11].
hunts were categorized as followed:
less than 10 MES, no or trivial shunt;
10—50 MES, moderate shunt;
more than 50 MES or curtain pattern, large shunt.
Passage of more than 50 microbubbles or a curtain pat-
ern appearing once during the procedure was required for
ercutaneous PFO closure.
FO closure
enous access was obtained through the femoral vein,
nder general anaesthesia. PFO and occluder size were
etermined from the TEE evaluation, and the maxi-
um PFO dimension was determined by measuring the
alloon-stretched diameter. Four different devices (Helex
; Amplatzer PFO occluder 5; PFO Star/Cardia Star 48;
ardioseal/Starﬂex 12) were implanted under ﬂuoroscopic
uidance with TEE monitoring. Patients were treated
ith aspirin 160mg once daily for six months to provide
ntithrombotic protection until full device endothelializa-
ion. Patients with a PFO Star closure received clopidogrel
5mg once daily for six weeks after device implementa-
ion. Treatment was withdrawn after six months. Prophylaxis
gainst Osler’s endocarditis was also recommended for the
rst six months after closure.
ollow-up
fter PFO closure, patients were followed by a neurologist
nd a cardiologist for clinical outcome and side effects.
he primary endpoint was recurrent stroke event, includ-
ng TIA or peripheral emboli; the secondary endpoint was
ersistence of a signiﬁcant residual R/L shunt on con-
rast TCD ultrasonography. Clinical, TTE, and contrast TCD
ltrasonography evaluations were carried out at three, six,
nd 12 months. In cases of signiﬁcant persisting shunt,
EE was performed at 12 months. Recurrent stroke event
ates were calculated as the ratio of the total number
f recurrent stroke events to the total number of follow-
p years since the ﬁrst stroke event, divided by 100 to
ield recurrent stroke event rates per 100 patient-years
8].
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Table 1 Patient characteristics.
Characteristic
Number of patients, n 66
Mean age (median), years 41.5 (43)
Women, n (%) 31 (47.0)
Smoker, n (%) 15 (22.7)
Controlled arterial hypertension, n
(%)
4 (6.1)
Controlled hyperlipaemia, n (%) 11 (16.7)
Scuba diver, n (%) 4 (6.1)
Atrial septal aneurysm, n (%) 34 (51.5%)
Frequency of stroke events before PFO closure, n (%)
1 47 (71.2)
2 10 (15.2)
3 7 (10.6)
4 2 (3.0)
Total number of stroke events
before PFO closure
96
Number of recurrent stroke events
before PFO closure
30
Number of recurrent stroke events
per 100 patient-years before PFO
closure
16.57
Mean delay between ﬁrst stroke
event and PFO closure (median),
2.74 (0.83)
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tatistical analysis
ontinuous variables were compared using a Wilcoxon test,
s variables did not present a normal distribution. Pro-
ortions were compared using Fisher’s exact test. The
umbers of ischaemic events before and after treatment
ere compared using the median test. A p-value of 0.05
as considered to be signiﬁcant. We used SAS version 8.0
tatistical software (SAS Institute Inc., Cary, NC, USA).
esults
atient characteristics
etween January 2000 and May 2005, 81 patients below 55
ears of age (45 men and 36 women) were referred con-
ecutively to undergo percutaneous transcatheter closure
f PFO. Fifteen of these patients were excluded from the
rocedure for the following reasons:
TIA only with no MRI lesion (n = 8);
coexisting cervical arterial dissection (n = 1);
hyperhomocysteinaemia related to the homozygote
C677T MTHFR gene mutation (n = 1; this patient is receiv-
ing treatment to normalize the homocysteinaemia);
hypercoagulable status related to factor V Leiden and
prothrombin G20210A gene mutation (n = 2);
moderate R/L shunt with 50 microbubbles or less, on
contrast TCD ultrasonography (n = 3). One of the three
patients with a moderate R/L shunt (45 microbubbles on
TCD) had a new stroke during the study period; the others
remain asymptomatic.
Percutaneous transcatheter closure of PFO was per-
ormed in 66 patients who fulﬁlled all the criteria for the
rocedure, and from whom written informed consent had
een obtained. Patient characteristics are summarized in
able 1.
Nineteen (28.8%) patients had experienced more than
ne stroke events before PFO closure (mean 2.6 recurrent
trokes; Table 1; Fig. 1) despite antithrombotic therapy that
ncluded at least aspirin (n = 14) and oral anticoagulation
n = 1). The mean observation period between the ﬁrst and
ast stroke before PFO closure was 6.2 years (median: four
ears) in these patients. Seven of these patients had one
r more recurrent stroke event in the year after the ﬁrst
troke.
The median delay between ﬁrst stroke and PFO closure
as signiﬁcantly longer in patients who had experi-
nced a recurrent stroke event before PFO closure (4.3
ears; range: three months to 22 years) than in patients
ho had experienced only one stroke before PFO clo-
ure (seven months; range: three months to seven years;
= 0.0001).
FO closureFO size was measured with a balloon in the ﬁrst 22 (33.3%)
atients, but the procedure was not performed thereafter.
he mean balloon-stretched dimension was 11mm (median:
0.5mm; range: 7—16mm).
P
A
uyears
Mean follow-up period after PFO
closure (median), years
3.73 (3.55)
An ASA was present in 34 patients (51.5%); the frequency
f stroke was not signiﬁcantly higher in patients with an ASA
han in patients with PFO alone.
Percutaneous PFO closure was successful in all 66
atients. One patient had an iliac thrombosis and pul-
onary embolism 27 days after the procedure, probably
ue to venous catheterization, and an asymptomatic intrac-
rdial thrombus on the PFO device was found in another
atient at the three-month follow-up consultation; both of
hese patients were treated successfully with warfarin. One
atient had a femoral arteriovenous ﬁstula that resolved
pontaneously. Two patients presented with an episode of
cute atrial ﬁbrillation a few days after device placement;
hese resolved quickly with medication.
eurological follow-up
ollow-up data were available from 65 patients; one patient
as lost to follow-up after moving back to the USA. During
he follow-up period (mean: 3.73 years, median: 3.5, range:
.36—6.75, total: 246 patient-years), no patient experi-
nced a recurrent stroke or TIA, compared with 30 recurrent
troke events during the time from the ﬁrst stroke event
ntil PFO closure (mean: 2.74 years, median: 0.83, range:
.22—22, total: 181 patient-years; p < 0.0001).ersisting residual shunt
residual shunt of more than 10 microbubbles at TCD
ltrasonography assessment was present in 29/57 (50.9%)
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oFigure 1. Delay between ﬁrst or recurrent stroke event (stacked
closure (plain columns) (n = 66). Before PFO closure, 19 patients pre
of 181 patient-years compared with no recurrent stroke events afte
patients evaluated three months after PFO closure, in 23/54
(42.6%) patients evaluated six months after PFO closure and
in 25/60 (41.7%) patients evaluated 12 months after PFO clo-
sure; a persisting shunt of more than 50 microbubbles was
present in 12 (20.0%) of these patients.
The presence of a residual R/L shunt on TCD did not
correlate with the type of device used. The ratio of
residual shunt to device used was 1:1 with Helex, 2:5
with AMPLATZER PFO occluder (40.0%), 23:48 with PFO
Star/Cardia Star (47.9%), and 3:12 with Cardioseal/Starﬂex
(25.0%).
TEE evaluation was carried out in 14/25 patients with
residual signiﬁcant shunt, and in 10/12 patients with a per-
sisting shunt of more than 50 microbubbles at the 12-month
follow-up TCD evaluation. In nine patients, the residual
shunt was related to the device (protrusion of one left arm
of the occluder into the right atrium, n = 1; persistent shunt
through the device and/or abnormal mobility of the right
disk and incomplete occlusion, n = 8).In four patients, persisting shunts were associated with
the presence of an additional atrial septal defect (ASD):
three patients had a small additional ASD (a second device
was implanted successfully in one of these patients, with
complete suppression of the residual shunt; a second
m
e
w
s
amns) and PFO closure (time 0), and follow-up duration after PFO
d with 30 recurrent stroke events during a total observation period
closure during a total follow-up period of 246 patient-years.
ttempt at closure was not judged to be necessary for the
ther two patients, who had tiny ASDs located close to the
orta) and one patient presented with a neo-ASD created
y the motion of a 38 Starﬂex device closing an aneurysmal
FO (this was closed successfully using an 8mm Amplatzer).
n one patient, no residual interatrial shunt was present,
ut an intrapulmonary shunt with bubbles coming from the
pper right pulmonary was seen at contrast echo.
iscussion
e limited the indication for percutaneous PFO closure to
atients below 55 years of age, with cryptogenic stroke and
FO associated with a signiﬁcant R/L shunt (> 50 microbub-
les or curtain pattern on contrast TCD). Only stroke events
roved by CT scan or MRI and reported in detail by a neurol-
gist were considered.
The balloon-stretched dimensions of the PFOs that were
easured were large (7—16mm), which indicates that a rel-
vant shunt described by contrast TEE and TCD is associated
ith large PFO. There was a 51.5% incidence of ASA in our
elected population, conﬁrming the impression that ASA is
ssociated with larger PFOs [3]. Our study illustrates the
440 F. van de Wyngaert et al.
Figure 2. PFO conﬁguration. A. Subcostal two-dimensional echo view of a 1-year-old child, showing the speciﬁc conﬁguration of the right
atrium, with the Eustachian valve directing the ﬂow from the IVC through the PFO to the left atrium; this echo view helps us to understand
how the funnel shape of the PFO and the conﬁguration of IVC-right atrium junction are playing a role in orienting thrombi from the IVC to
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Rhe left atrium. B. TEE echo view before PFO closure: the PFO looks
. Subcostal two-dimensional echo view after PFO closure: the PFO
bright image between right atrium and left atrium), and the PFO n
otential beneﬁts of contrast TCD for detection, functional
valuation of the shunt [12], and postprocedure control [13].
Before closure, 30 recurrent stroke events were observed
uring the 181 years of follow-up time from the ﬁrst stroke
vent to PFO closure (16.57 stroke events per 100 patient-
ears) compared with no recurrent stroke events (including
IA) after closure during a total of 246 years of follow-up
p < 0.0001). Of the 19 patients who had a recurrent stroke
vent before PFO closure, seven had a new stroke in the year
fter the ﬁrst event. In our study, the observation period
efore PFO closure was signiﬁcantly longer (median 4.3
ears) in patients who had a recurrent stroke event before
FO closure than in patients who only had one stroke before
FO closure (median: seven months; p = 0.0001). Patients
ho only had one stroke before PFO closure may have been
elected for device closure earlier, preventing the recur-
ence of a neurological event.
Our results suggest that percutaneous PFO closure is
seful in preventing secondary stroke in young patients pre-
enting with large PFOs, and introduce reservations about
he beneﬁts of medical treatment in this population.
The high percentage (41.7%) of persisting shunts after
FO closure raises many questions and emphasizes the need
or critical evaluation of the results of PFO closure. On
EE examination, residual shunts were related either to the
evice (incorrect device positioning or device not water-
ight) or to an additional ASD not covered by the device.
one of the ASDs were seen on TEE before the percutaneous
rocedure, suggesting that PFO closure was necessary to
llow a shunt through that small interatrial communication.
The high percentage of persisting shunts, and the com-
lete absence of recurrent stroke events (including TIA) in
his young, carefully selected population with cryptogenic
troke, seem to be contradictory ﬁndings. This inconsistency
as led us to reconsider the goal of percutaneous PFO clo-
ure: whether it should be to abolish R/L shunt or to prevent
he recurrence of stroke (the real endpoint)? Modifying the
onﬁguration of the interatrial septum by device placement
ay explain the lack of recurrent stroke or TIA despite the
resence of a residual shunt. Anatomically, PFO is a funnel
f varying length bounded by the septum secundum and sep-
um primum. The PFO has an asymmetric conﬁguration, witha funnel with a larger oriﬁce on the right side than on the left side.
my is modiﬁed—both septa became coplanar due to the prosthesis
ger resembles a funnel.
larger oriﬁce on the right side than on the left side (Fig. 2).
FO function during fetal life is to direct the inferior vena
ava (IVC) ﬂow to the left atrium, allowing the blood oxy-
enated by the placenta to be directed preferentially to the
rain. PFO anatomy is modiﬁed with PFO device placement
14]; both septa became coplanar and the PFO is no longer
funnel. Thanks to this new anatomy, clots could be less
ikely allowed to cross the persisting shunt from the right
irculation to the left circulation and then to the brain.
The relationship between PFO and cryptogenic stroke has
een demonstrated [1], but the exact mechanism remains
nknown. The size and the funnel shape of the PFO are quite
ifferent to the simple hole of an ASD, and probably play an
mportant role in this relationship.
In conclusion, contrast TCD is helpful in the selection of
atients for PFO closure. Large R/L shunts seem to require
FO closure to prevent recurrent stroke events, but con-
rast TCD detected a high incidence of residual R/L shunts
fter PFO closure. However, the absence of recurrent stroke
vents after PFO closure, even in the presence of persist-
ng R/L shunt, suggests that alteration of PFO conﬁguration
nduced by transcatheter closure may prevent stroke. Fur-
her larger studies are needed to conﬁrm these data.
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